csirt@kutim:~/threat-intel/cve/CVE-2024-49978

Katalog CVE

CVSS 5.5 · Medium EPSS 0,66%

Kerentanan NULL Pointer Dereference pada linux kernel. Skor CVSS 3.1 5.5 (Medium) menurut NVD.

Deskripsi (NVD)

In the Linux kernel, the following vulnerability has been resolved: gso: fix udp gso fraglist segmentation after pull from frag_list Detect gso fraglist skbs with corrupted geometry (see below) and pass these to skb_segment instead of skb_segment_list, as the first can segment them correctly. Valid SKB_GSO_FRAGLIST skbs - consist of two or more segments - the head_skb holds the protocol headers plus first gso_size - one or more frag_list skbs hold exactly one segment - all but the last must be gso_size Optional datapath hooks such as NAT and BPF (bpf_skb_pull_data) can modify these skbs, breaking these invariants. In extreme cases they pull all data into skb linear. For UDP, this causes a NULL ptr deref in __udpv4_gso_segment_list_csum at udp_hdr(seg->next)->dest. Detect invalid geometry due to pull, by checking head_skb size. Don't just drop, as this may blackhole a destination. Convert to be able to pass to regular skb_segment.

Rincian

Terbit di NVD
21 Oktober 2024
Terakhir diubah
4 Agustus 2026
Status NVD
Modified
CVSS 3.1
5.5 (Medium), sumber NVD
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-476: NULL Pointer Dereference
EPSS (30 hari)
0,66% peluang dieksploitasi; lebih tinggi dari 50,2% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
linux linux kernel Versi 5.6 hingga sebelum 6.1.113
linux linux kernel Versi 6.2 hingga sebelum 6.6.55
linux linux kernel Versi 6.7 hingga sebelum 6.10.14
linux linux kernel Versi 6.11 hingga sebelum 6.11.3
linux linux kernel Versi 6.12 rc1

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.